UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics and Aid FDA Registration

SHENZHEN, China, Aug. 28, 2024 -- UTime Limited (NASDAQ: WTO) has announced the signing of a non-disclosure agreement with Bowen Therapeutics Inc for the acquisition of the Bowen Therapeutics laboratory at UMASS Medical School. This strategic move signifies UTime’s expansion into the global vaccine market and supports the registration of the relevant vaccine with the U.S. Food and Drug Administration (FDA).

The acquisition is driven by the urgent global need for an effective monkeypox vaccine. Monkeypox, an infectious disease caused by the monkeypox virus, has seen outbreaks in various parts of the world in recent years, raising significant public health concerns. The World Health Organization reports cases of monkeypox in numerous countries, highlighting the pressing need for effective prevention, control measures, and vaccines.

Bowen Therapeutics, the company UTime aims to acquire, focuses on the research and development of vaccines for infectious diseases. The laboratory has published multiple research papers on the monkeypox virus and proposed several potential vaccine designs. One notable development is the Noval hexavalent recombinant protein vaccine, designed using the latest recombinant technology based on the monkeypox virus's characteristics. This technology aims to enhance the level of virus-neutralizing antibodies and significantly improve the vaccine's protective effect.

Under the terms of the NDA, UTime will assume control of the Bowen Therapeutics laboratory at UMASS Medical School, overseeing ongoing clinical trials and future vaccine development programs. UTime will leverage its resources and expertise to expedite the FDA registration process for the monkeypox vaccine. This acquisition is expected to enable broader global application and promotion of Bowen’s core technologies and products.

The transaction is subject to negotiation and customary closing conditions, including regulatory approvals, and is anticipated to complete all legal and commercial formalities within a few months. However, there is no guarantee that the transaction will be completed within the expected timeframe or at all.

Hengcong Qiu, Chief Executive Officer of UTime, remarked that acquiring Bowen Therapeutics is a significant milestone in UTime's exploration of the medical and healthcare sector and a critical step in globalizing its vaccine business. He emphasized the company's commitment to addressing global public health issues through innovation and technology. The integration of Bowen's resources and technology will accelerate UTime’s R&D capabilities, particularly in vaccine development, given the current global monkeypox outbreak concerns.

With its investment in monkeypox vaccine development, UTime is poised to play a more prominent role in the global vaccine market. This acquisition represents a strategic realignment and a proactive response to global public health challenges, showcasing the crucial role companies can play in global health.

UTime Limited, established in 2008, provides cost-effective mobile devices globally, aiding low-income individuals in both established and emerging markets, including the United States, India, South Asia, and Africa, in accessing updated mobile technology. Since 2024, UTime has focused on transforming health and wellness through innovative medical wearable technologies. Utilizing cutting-edge research and strategic partnerships, UTime aims to offer effective solutions for disease prevention and health management worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!